Reviewing Athersys Inc. (ATHX)’s and Nabriva Therapeutics plc (NASDAQ:NBRV)’s results

Athersys Inc. (NASDAQ:ATHX) and Nabriva Therapeutics plc (NASDAQ:NBRV) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athersys Inc. 24.29M 8.71 24.28M -0.21 0.00
Nabriva Therapeutics plc 9.66M 19.78 114.78M -2.31 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 shows Athersys Inc. and Nabriva Therapeutics plc’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Athersys Inc. -99.96% -58.7% -44.6%
Nabriva Therapeutics plc -1,188.20% -124.4% -107.4%

Risk & Volatility

Athersys Inc.’s current beta is 0.47 and it happens to be 53.00% less volatile than Standard & Poor’s 500. Competitively, Nabriva Therapeutics plc’s beta is 2.31 which is 131.00% more volatile than Standard & Poor’s 500.


The Current Ratio and a Quick Ratio of Athersys Inc. are 4.6 and 4.6. Competitively, Nabriva Therapeutics plc has 7.3 and 7.3 for Current and Quick Ratio. Nabriva Therapeutics plc’s better ability to pay short and long-term obligations than Athersys Inc.

Analyst Ratings

In next table is delivered Athersys Inc. and Nabriva Therapeutics plc’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Athersys Inc. 0 0 2 3.00
Nabriva Therapeutics plc 0 0 0 0.00

Athersys Inc.’s upside potential currently stands at 386.11% and an $7 average target price.

Insider & Institutional Ownership

Roughly 23.7% of Athersys Inc. shares are held by institutional investors while 58% of Nabriva Therapeutics plc are owned by institutional investors. Insiders held roughly 2.1% of Athersys Inc.’s shares. Competitively, Nabriva Therapeutics plc has 0.1% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Athersys Inc. 1.97% -2.52% -19.69% -22.89% 15.67% 7.64%
Nabriva Therapeutics plc 5.45% 12.11% 9.79% -18.08% -60.92% 45.89%

For the past year Athersys Inc. was less bullish than Nabriva Therapeutics plc.


On 8 of the 11 factors Athersys Inc. beats Nabriva Therapeutics plc.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.